These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 17172407)
1. Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. Williamson MJ; Blank JL; Bruzzese FJ; Cao Y; Daniels JS; Dick LR; Labutti J; Mazzola AM; Patil AD; Reimer CL; Solomon MS; Stirling M; Tian Y; Tsu CA; Weatherhead GS; Zhang JX; Rolfe M Mol Cancer Ther; 2006 Dec; 5(12):3052-61. PubMed ID: 17172407 [TBL] [Abstract][Full Text] [Related]
2. Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib). Niewerth D; Jansen G; Riethoff LF; van Meerloo J; Kale AJ; Moore BS; Assaraf YG; Anderl JL; Zweegman S; Kaspers GJ; Cloos J Mol Pharmacol; 2014 Jul; 86(1):12-9. PubMed ID: 24737138 [TBL] [Abstract][Full Text] [Related]
3. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Ruiz S; Krupnik Y; Keating M; Chandra J; Palladino M; McConkey D Mol Cancer Ther; 2006 Jul; 5(7):1836-43. PubMed ID: 16891470 [TBL] [Abstract][Full Text] [Related]
4. Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A. Kale AJ; McGlinchey RP; Lechner A; Moore BS ACS Chem Biol; 2011 Nov; 6(11):1257-64. PubMed ID: 21882868 [TBL] [Abstract][Full Text] [Related]
5. Novel proteasome inhibitors to overcome bortezomib resistance. Ruschak AM; Slassi M; Kay LE; Schimmer AD J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441 [TBL] [Abstract][Full Text] [Related]
6. Effect of noncompetitive proteasome inhibition on bortezomib resistance. Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154 [TBL] [Abstract][Full Text] [Related]
7. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Chauhan D; Catley L; Li G; Podar K; Hideshima T; Velankar M; Mitsiades C; Mitsiades N; Yasui H; Letai A; Ovaa H; Berkers C; Nicholson B; Chao TH; Neuteboom ST; Richardson P; Palladino MA; Anderson KC Cancer Cell; 2005 Nov; 8(5):407-19. PubMed ID: 16286248 [TBL] [Abstract][Full Text] [Related]
9. Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells. Fuchs O; Provaznikova D; Marinov I; Kuzelova K; Spicka I Cardiovasc Hematol Disord Drug Targets; 2009 Mar; 9(1):62-77. PubMed ID: 19275578 [TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer. Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822 [TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma. Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533 [TBL] [Abstract][Full Text] [Related]
12. In vivo imaging of proteasome inhibition using a proteasome-sensitive fluorescent reporter. Momose I; Tatsuda D; Ohba S; Masuda T; Ikeda D; Nomoto A Cancer Sci; 2012 Sep; 103(9):1730-6. PubMed ID: 22676179 [TBL] [Abstract][Full Text] [Related]
13. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib. Cvek B; Dvorak Z Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411 [TBL] [Abstract][Full Text] [Related]
14. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Fernández Y; Verhaegen M; Miller TP; Rush JL; Steiner P; Opipari AW; Lowe SW; Soengas MS Cancer Res; 2005 Jul; 65(14):6294-304. PubMed ID: 16024631 [TBL] [Abstract][Full Text] [Related]
15. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib. Berkers CR; Leestemaker Y; Schuurman KG; Ruggeri B; Jones-Bolin S; Williams M; Ovaa H Mol Pharm; 2012 May; 9(5):1126-35. PubMed ID: 22432738 [TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Kazi A; Lawrence H; Guida WC; McLaughlin ML; Springett GM; Berndt N; Yip RM; Sebti SM Cell Cycle; 2009 Jun; 8(12):1940-51. PubMed ID: 19471122 [TBL] [Abstract][Full Text] [Related]
17. Natural compounds with proteasome inhibitory activity for cancer prevention and treatment. Yang H; Landis-Piwowar KR; Chen D; Milacic V; Dou QP Curr Protein Pept Sci; 2008 Jun; 9(3):227-39. PubMed ID: 18537678 [TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitors: an expanding army attacking a unique target. Kisselev AF; van der Linden WA; Overkleeft HS Chem Biol; 2012 Jan; 19(1):99-115. PubMed ID: 22284358 [TBL] [Abstract][Full Text] [Related]
19. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072 [TBL] [Abstract][Full Text] [Related]
20. Synthesis of salinosporamide A and its analogs as 20S proteasome inhibitors and SAR summarization. Ma Y; Qu L; Liu Z; Zhang L; Yang Z; Zhang L Curr Top Med Chem; 2011 Dec; 11(23):2906-22. PubMed ID: 21824108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]